stoxline Quote Chart Rank Option Currency Glossary
Affimed N.V. (AFMD)
6.3  -0.44 (-6.53%)    06-18 11:24
Open: 6.7
High: 6.73
Volume: 70,327
Pre. Close: 6.74
Low: 6.26
Market Cap: 96(M)
Technical analysis
2024-06-18 10:47:40 AM
Short term     
Mid term     
Targets 6-month :  10.45 1-year :  12.2
Resists First :  8.94 Second :  10.45
Pivot price 6.16
Supports First :  5.76 Second :  3.79
MAs MA(5) :  6.86 MA(20) :  5.77
MA(100) :  5.57 MA(250) :  5.25
MACD MACD :  0.4 Signal :  0.3
%K %D K(14,3) :  58.2 D(3) :  60.7
RSI RSI(14): 58
52-week High :  8.94 Low :  2.24
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AFMD ] has closed below upper band by 40.7%. Bollinger Bands are 124.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.12 - 7.15 7.15 - 7.17
Low: 6.58 - 6.62 6.62 - 6.65
Close: 6.67 - 6.74 6.74 - 6.79
Company Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Headline News

Mon, 17 Jun 2024
Affimed to Post Q2 2024 Earnings of ($1.26) Per Share, HC Wainwright Forecasts (NASDAQ:AFMD) - MarketBeat

Sat, 15 Jun 2024
Affimed (NASDAQ:AFMD) Price Target Raised to $25.00 at Laidlaw - Defense World

Fri, 14 Jun 2024
Affimed's (AFMD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Fri, 14 Jun 2024
Affimed N.V. (NASDAQ:AFMD) Upgraded by Laidlaw - Yahoo Finance

Thu, 13 Jun 2024
Affimed N.V.: Q1 Earnings Snapshot - Milford Mirror

Wed, 12 Jun 2024
Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 15 (M)
Shares Float 14 (M)
Held by Insiders 6 (%)
Held by Institutions 33.7 (%)
Shares Short 231 (K)
Shares Short P.Month 219 (K)
Stock Financials
EPS -7.72
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.84
Profit Margin 0 %
Operating Margin -382.5 %
Return on Assets (ttm) -43.5 %
Return on Equity (ttm) -100.6 %
Qtrly Rev. Growth -58.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.91
EBITDA (p.s.) -6.74
Qtrly Earnings Growth 0 %
Operating Cash Flow -110 (M)
Levered Free Cash Flow -106 (M)
Stock Valuations
PE Ratio -0.86
PEG Ratio 0
Price to Book value 1.7
Price to Sales 7.18
Price to Cash Flow -0.91
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android